Healthcare Resource Utilization Costs in People With Cognitive Impairment Associated With Schizophrenia: A US Non-Interventional Cohort Study of Real World Data
Author(s)
Ling Zhang, MD, MS, MPH1, Theresa Cassidy, MPH1, Patrick Keeler, PhD2, Sebastien Tulliez, MBA2, Rashmi Patel, MD, PhD3;
1Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 3University of Cambridge, Department of Psychiatry, Cambridge, United Kingdom
1Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 2Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 3University of Cambridge, Department of Psychiatry, Cambridge, United Kingdom
Presentation Documents
OBJECTIVES: This non-interventional, retrospective study used de-identified real-world data from US-based administrative claims and electronic health records in the Optum Market Clarity database to assess healthcare resource utilization among patients with cognitive impairment associated with schizophrenia (CIAS).
METHODS: Adult US patients with ≥2 schizophrenia diagnosis claims (October 1, 2016-March 31, 2022) and ≥1 year of continuous enrollment pre-index date (first schizophrenia diagnosis) were included. CIAS was identified using the pre-defined sum score method: score >0, CIAS present (CIAS-Y); score ≤0, no CIAS (CIAS-N). Medical visit, medication, and total costs per person per year (PPPY), and number of visits PPPY were analyzed. Adjusted mean cost differences (95% confidence interval [CI]) were estimated using two-part log-linked gamma linear regression. Covariates included demographics, psychiatric diagnoses and medications, Elixhauser comorbidities and pre-index healthcare visits. To accurately estimate mean difference, the top 1 percentile were excluded.
RESULTS: 181,630 patients were included in this analysis (CIAS-Y: n=43,458; CIAS-N: n=138,172). Mean total costs were $56,326 for CIAS-Y and $32,386 for CIAS-N (mean difference [CI]: $19,477 [17,766, 21,289]). Mean medication costs were $7920 and $6815 for CIAS-Y and CIAS-N, respectively (mean difference [CI]: $870 [503, 1270]). Mean medical costs were $48,406 for CIAS-Y and $25,571 for CIAS-N (mean difference [CI]: $20,529 [18,840, 22,176]). Mean medical cost by encounter type for CIAS-Y and CIAS-N, respectively: emergency room costs were $4241 and $2863 (mean difference [CI]: $1272 [1117, 1436]); inpatient costs were $25,657 and $12,569 (mean difference [CI]: $11,279 [10,072, 12,486]); outpatient costs were $18,509 and $10,140 (mean difference [CI]: $5743 [5069, 6457]). The CIAS-Y group had a higher mean number of inpatient (mean difference [CI]: 0.61 [0.55, 0.67]) and outpatient visits (13.08 [10.78, 15.32]).
CONCLUSIONS: Patients with CIAS had greater disease burden than patients without CIAS, reflected by a 60% mean difference in total healthcare utilization costs.
FUNDING: Boehringer Ingelheim (1346-0085).
METHODS: Adult US patients with ≥2 schizophrenia diagnosis claims (October 1, 2016-March 31, 2022) and ≥1 year of continuous enrollment pre-index date (first schizophrenia diagnosis) were included. CIAS was identified using the pre-defined sum score method: score >0, CIAS present (CIAS-Y); score ≤0, no CIAS (CIAS-N). Medical visit, medication, and total costs per person per year (PPPY), and number of visits PPPY were analyzed. Adjusted mean cost differences (95% confidence interval [CI]) were estimated using two-part log-linked gamma linear regression. Covariates included demographics, psychiatric diagnoses and medications, Elixhauser comorbidities and pre-index healthcare visits. To accurately estimate mean difference, the top 1 percentile were excluded.
RESULTS: 181,630 patients were included in this analysis (CIAS-Y: n=43,458; CIAS-N: n=138,172). Mean total costs were $56,326 for CIAS-Y and $32,386 for CIAS-N (mean difference [CI]: $19,477 [17,766, 21,289]). Mean medication costs were $7920 and $6815 for CIAS-Y and CIAS-N, respectively (mean difference [CI]: $870 [503, 1270]). Mean medical costs were $48,406 for CIAS-Y and $25,571 for CIAS-N (mean difference [CI]: $20,529 [18,840, 22,176]). Mean medical cost by encounter type for CIAS-Y and CIAS-N, respectively: emergency room costs were $4241 and $2863 (mean difference [CI]: $1272 [1117, 1436]); inpatient costs were $25,657 and $12,569 (mean difference [CI]: $11,279 [10,072, 12,486]); outpatient costs were $18,509 and $10,140 (mean difference [CI]: $5743 [5069, 6457]). The CIAS-Y group had a higher mean number of inpatient (mean difference [CI]: 0.61 [0.55, 0.67]) and outpatient visits (13.08 [10.78, 15.32]).
CONCLUSIONS: Patients with CIAS had greater disease burden than patients without CIAS, reflected by a 60% mean difference in total healthcare utilization costs.
FUNDING: Boehringer Ingelheim (1346-0085).
Conference/Value in Health Info
2025-05, ISPOR 2025, Montréal, Quebec, CA
Value in Health, Volume 28, Issue S1
Code
EE167
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
SDC: Mental Health (including addition)